A pension fund filed suit in Delaware to challenge BridgeBio Pharma Inc.'s $175 million buyout of Eidos Therapeutics Inc., claiming Eidos board members tied to partial parent BridgeBio misled investors into approving the “patently unfair” deal after spurning a better offer from another suitor.
The proposed class action, made public Thursday in Delaware Chancery Court, targets BridgeBio and three Eidos ex-directors, including BridgeBio’s CEO-founder, a KKR & Co. partner who previously sat on BridgeBio’s board, and the former chief scientific officer of both companies.
The lawsuit accuses them of pushing through the $73.26-per-share buyout by BridgeBio, which closed in January, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.